ReviewJournal of nanobiotechnology2022
Low dimensional nanomaterials for treating acute kidney injury.
Review in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Incidence and risk factors of acute kidney injury following Stanford type A aortic dissection surgery: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- Hesperetin loaded fucoidan selenium nanoparticles alleviate cisplatin induced acute kidney injury via antioxidant and cGAS STING pathway regulation.Discover nano · 2026Article
- Nanomachines Based on Inner Ultrasonic Multiple Scattering for Ameliorating Renal Function.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Improved bioavailability and anti-nephrotoxicity efficacy of polydatin on cisplatin-induced AKIInternational journal of pharmaceutics: X · 2025Article
- Functional Carbon-Based Materials for Blood Purification: Recent Advances Toward Improved Treatment of Renal Failure and Patient Quality of Life.Bioengineering (Basel, Switzerland) · 2025Review
- Harnessing the power of nanoagents in acute kidney injury: A versatile platform for imaging and treatment.Coordination chemistry reviews · 2025Article
- Living Microalgae-Based Magnetic Microrobots for Calcium Overload and Photodynamic Synergetic Cancer Therapy.Advanced healthcare materials · 2025Article
- Application of Nanomaterial-Mediated Ferroptosis Regulation in Kidney Disease.International journal of nanomedicine · 2025Review
- Silencing RPL11 attenuates acute kidney injury by suppressing tubular apoptosis and macrophage-driven inflammation.Frontiers in immunology · 2025Article
- Roles of MXenes in biomedical applications: recent developments and prospects.Journal of nanobiotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
Acute kidney injury (AKI) is one of the most common severe complications among hospitalized patients. In the absence of specific drugs to treat AKI, hemodialysis remains the primary clinical treatment for AKI patients. AKI treatment has received significant attention recently due to the excellent drug delivery capabilities of low-dimensional nanomaterials (LDNs) and their unique therapeutic effects. Diverse LDNs have been proposed to treat AKI, with promising results and the potential for future clinical application. This article aims to provide an overview of the pathogenesis of AKI and the recent advances in the treatment of AKI using different types of LDNs. In addition, it is intended to provide theoretical support for the design of LDNs and implications for AKI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.